Epstein Secrets

ncluding all the major viral hemorrhagic fever viruses (VHF; ebolavirus, marburgvirus Crimean Congo=nbsp;hemorrhagic fever virus, Lassa fever virus, Rift Valley fever vir=s, Dengue virus, and Yellow fever virus). (Kindly see belo= abstract of manuscript just being submitted). In addition, in collaboration wi

evices suitable f=r working in developing countries, and may be powered and run by a cell phone or smart device. • Current CDC approved EZ1-RT-P=R Taqman assay has LOD of 5,000 PFU/ml. This works when patient is&nbs=;febrile, i.e. has overt symptoms and may be contagious. • Next level of assay needs

ts, including all the major viral hemorrhagic fever viruses (VHF; ebolavirus, marburgvirus Crimean Cong= hemorrhagic fever virus, Lassa fever virus, Rift Valley fever v=rus, Dengue virus, and Yellow fever virus). (Kindly see b=low abstract of manuscript just being submitted). In addition, =n collaboration wi

ricated devices that w=ll allow for electronic detection, obviating the need for expens=ve hardware used in most fluorescent detection schemes (i.e. Taqman a=says). As such, we are poised to combine these technologie= for rapidly identifying and providing quantitative viral load fo= all the VHF, Variol

ncluding all the major viral hemorrhagic fever viruses (VHF; ebolavirus, marburgvirus Crimean Congo=nbsp;hemorrhagic fever virus, Lassa fever virus, Rift Valley fever vir=s, Dengue virus, and Yellow fever virus). (Kindly see belo= abstract of manuscript just being submitted). In addition, in collaboration wi

devices suitable f=r working in developing countries, and may be powered and run by a cell phone or smart device. • Current CDC approved EZ1-RT-P=R Taqman assay has LOD of 5,000 PFU/ml. This works when patient is&nbs=;febrile, i.e. has overt symptoms and may be contagious. • Next level of assay needs